Health intelligence company Sema4 and artificial intelligence (AI) informatics company VieCure have entered a strategic collaboration to enable oncologists to provide personalised care to the patients.
The alliance allows Sema4 scientists to access patient data from the VCurePrecision EMR platform with the consent of the patients and analyse the data using its Centrellis health intelligence platform.
This initiative is expected to improve the diagnosis, treatment, and prevention of cancer through data-driven insights and predictive modelling.
Furthermore, it will allow oncologists using the VCurePrecision EMR to access real-time insights that help in point-of-care decision-making and clinical trial identification for patients.
This strategic collaboration also enables healthcare providers to recommend Sema4’s molecular testing for cancer through the VCurePrecision platform.
VieCure CEO Fred Ashbury said: “Oncologists are embracing the paradigm shift toward data-driven precision medicine, but they face myriad clinical workflow and content-related challenges. Our system combines patient data with leading scientific knowledge to generate and manage individualised treatment plans throughout the patient’s diagnosis and care journey.
“We are excited to deliver even better insights to the providers who use our smart EMR through Sema4’s deep knowledge of multi-dimensional data analysis, predictive modelling, and advanced genetic testing.”
Private practice cancer centres and large provider organisations are claimed to have already implemented VieCure’s oncology-specific and AI-enabled VCurePrecision platform. It works as a point-of-care solution to collect, curate, and streamline information such as molecular testing and imaging.
Commenting on the partnership with VieCure, Sema4 CEO and president James Coffin said: “By teaming up with VieCure, we are able to partner with oncologists and healthcare systems to offer a full cancer care platform that includes real-time point-of-care precision oncology insights, research support, and clinical trial recruitment.
“This collaboration builds on our commitment to use the latest advances in genomics and real-world clinical data to give oncologists and their patients a critical edge in battling cancer.”